Ironwood Pharmaceuticals, Inc. (IRWD) Stock Price & Analysis

Ironwood Pharmaceuticals, Inc. (IRWD) closed at USD 3.61 on Wednesday, October 28, 2026, up 2.85% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 3.51; the Oct 28, 2026 session ranged USD 3.46–3.63 on volume of 1,411,305 shares. Market capitalization is $596.52M, with a 52-week range of USD 1.47–5.78 (NMS). Source: Nexqual, retrieved October 29, 2026 at 07:41 UTC.

Also available as compact Markdown for AI agents: nexqual.com/IRWD.md

Key facts (IRWD)

• Last four reported quarters (through Jun 30, 2026): revenue $389M, net income $130M (33.4% margin) (SEC filings).
• Valuation: P/E 4.6x (avg 414.4x at the last 2 fiscal year-ends).
• Insider open-market sales, last ~7 months: 2 Form 4 filings, $659K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 1 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.25 on a 1–5 scale) (4 analysts), mean target USD 6.1 (range 3.7–10).
• Total return with dividends: 1Y +139.1% vs S&P 500 +13.6%; 5Y -71.7% vs S&P 500 +79.8%.
• Next earnings: 2026-11-05, EPS estimate USD 0.31, revenue estimate $122M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (IRWD)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (IRWD)

P/E 4.6x · P/S 1.5x · Earnings yield 21.77%

P/E at fiscal year-ends: Dec 2025 22.9x, Dec 2024 805.9x.

Insider sales (SEC Form 4, open-market, last ~7 months) (IRWD)

2 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (IRWD)

Consensus Buy (mean 2.25 on a 1–5 scale), 4 analysts; mean target USD 6.1 (low 3.7, high 10).

Total return (dividends reinvested) (IRWD)

IRWD earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

IRWD recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

IRWD suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 26, 2026.

Companies that name IRWD in their SEC reports

IRWD company outlook (results filed Aug 6, 2026)

• “(linaclotide) U.S. net sales guidance to $1.15 - $1.20 billion, representing greater than 30% increase year-over-year;”

Analysts expect $121.6M for the current quarter, 89.7% below the midpoint of the company's guidance ($1.18B).

Quoted word-for-word from the SEC 8-K results press release.

IRWD analyst estimates and revisions

IRWD options: expected move

Options price a move of about ±31.6% (±$1.15) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±19.1% on average.

30-day implied volatility 67.4% vs 48.5% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 07:41 UTC)

Technical Analysis (IRWD)

Nexqual's technical model rates IRWD "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 07:41 UTC.

Analyst Ratings (IRWD)

Wall Street analysts rate IRWD "Buy" based on 4 analysts, with a mean price target of USD 6.1 (range USD 3.7–10), per Nexqual as of October 29, 2026 at 07:41 UTC.

Earnings (IRWD)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 07:41 UTC.

Financials & Fundamentals (IRWD)

Source: Nexqual, October 29, 2026 at 07:41 UTC.

Financial Health Score (IRWD)

Nexqual rates Ironwood Pharmaceuticals, Inc.'s overall financial health "Solid" across five dimensions, as of October 29, 2026 at 07:41 UTC.

Ownership (IRWD)

Source: Nexqual, October 29, 2026 at 07:41 UTC.

Leadership (IRWD)

Ironwood Pharmaceuticals, Inc. is led by Thomas A. McCourt, CEO & Director, per Nexqual as of October 29, 2026 at 07:41 UTC.

Major Backers & Investors (IRWD)

Notable institutional backers of Ironwood Pharmaceuticals, Inc. include Armistice Capital, LLC, Sarissa Capital Management, LP, Bank of America Corporation, according to Nexqual as of October 29, 2026 at 07:41 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 07:41 UTC.

From Ironwood Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• FDA regulations, drug-device combination products are subject to current GMP requirements applicable to both drugs and devices, including the Quality System Regulations applicable to medical devices.
• We actively seek to protect the proprietary technology that we consider important to our business, including pursuing patents that cover our products, compositions, and formulations, their methods of use and the processes for their manufacture, as well as any other relevant inventions and improvements that are commercially important to the development of our business.

Partnerships

• License Agreement with AbbVie (All countries other than the countries and territories of North America, China (including Hong Kong and Macau), and Japan) In April 2009, we entered into a license agreement with Almirall, S.A., or Almirall, or the European License Agreement, to develop and commercialize linaclotide in Europe (including the Commonwealth of Independent States and Turkey) for the treatment of IBS-C, CIC, and other GI conditions.
• In October 2012, we entered into a collaboration agreement with AstraZeneca to co-develop and co-commercialize linaclotide in China (including Hong Kong and Macau).

Legal & Regulatory Risks (Item 1A, quoted)

• We may be subject to privacy and security laws in the various jurisdictions, both inside and outside the U.S., in which we operate and/or obtain or store personally identifiable information, such as the E.U.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 07:41 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt